Regentis Biomaterials
RGNT
3 hedge funds and large institutions have $1.89M invested in Regentis Biomaterials in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$1.73M |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$131K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$71.4K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RA
1
Rosalind Advisors
Toronto,
Ontario, Canada
| $1.7M | +$1.73M | +251,510 | New |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $127K | +$131K | +19,093 | New |
|
|
3
Citadel Advisors
Miami,
Florida
| $70.2K | +$71.4K | +10,412 | New |
|
RGNT Hedge Fund Activity: Q4 2025 in Review
3 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Regentis Biomaterials (RGNT) for Q4 2025, worth a combined $1.89M.
Buyers outnumbered sellers: 3 funds opened new RGNT positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Rosalind Advisors, opening a new position worth an estimated $1.73M.
- 3 institutional investors held Regentis Biomaterials (RGNT) as of Q4 2025, up from 0 in Q3 2025.
- Funds reported $1.89M of Regentis Biomaterials stock for Q4 2025.
- 3 funds opened new Regentis Biomaterials positions in Q4 2025 and 0 closed out, a net change of +3 holders.
- The largest Regentis Biomaterials buyer in Q4 2025 was Rosalind Advisors, an estimated $1.73M added.
Based on aggregated 13F filings for Q4 2025.